NCT05388058
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least a 4 out of 10 severity of neuropathy pain and/or tingling
Exclusions: Patients with evidence of residual cancer; Patients with pre-existing neuropathy prior to chemotherapy
https://ClinicalTrials.gov/show/NCT05388058